KEGG   DRUG: Lamivudine, nevirapine and zidovudine
Entry
D11521            Mixture   Drug                                   

Name
Lamivudine, nevirapine and zidovudine
Component
Lamivudine [DR:D00353], Nevirapine [DR:D00435], Zidovudine [DR:D00413]
Remark
ATC code: J05AR05
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Lamivudine is a substrate of OCT2, MATE1 and MATE2-K.
Nevirapine is a substrate and an inducer of CYP3A and CYP2B6.
Zidovudine is metabolized by UDP-glucuronosyltransferase (UGT).
Target
HIV-1 reverse transcriptase [KO:K24802]
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], CYP2B6 [HSA:1555], UGT [KO:K00699]
Transporter: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244], SLC47A2 [HSA:146802]
Interaction
CYP induction: CYP3A [HSA:1576 1577 1551], CYP2B6 [HSA:1555]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR05 Zidovudine, lamivudine and nevirapine
      D11521  Lamivudine, nevirapine and zidovudine
Antiinfectives [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV reverse transcriptase inhibitor
    D11521  Lamivudine, nevirapine and zidovudine
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11521
 Drug transporters
  D11521
Other DBs
PubChem: 384585497

» Japanese version   » Back

DBGET integrated database retrieval system